CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing number of industry-academia collaborations
4.1.2. Growing research activity, funding for R&D
4.1.3. Innovations in research antibodies technologies
4.1.4. Rising stem cells and neurobiology research
4.2. Market Restraints & Challenges
4.2.1.Stringent government regulations
4.2.2. Cost- and time-intensive antibody development processes
4.3. Market Opportunities
4.3.1. Growing demand for personalised medicine and protein therapeutics
4.3.2. Growth in stem cell and neurobiology research
CHAPTER 5. GLOBAL RESEARCH ANTIBODIES MARKET – BY TECHNOLOGY
5.1. Introduction
5.2. Western blotting
5.3. Enzyme-linked immunosorbent assay (ELISA)
5.4. Flow cytometry
5.5. Immunoprecipitation
5.6. Immunofluorescence
5.7. Immunohistochemistry
5.8. Other technologies
CHAPTER 6. GLOBAL RESEARCH ANTIBODIES MARKET – BY PRODUCT
6.1.Introduction
6.2. Reagents
6.2.1. Media & sera
6.2.2. Stains & Dyes
6.2.3. Fixatives
6.2.4. Buffers
6.2.5. Solvents
6.2.6. Enzymes
6.2.7. Probes
6.2.8. Other reagents
6.3. Antibodies
6.3.1. Antibodies, by type
6.3.1.1. Primary antibodies
6.3.1.2. Secondary antibodies
6.3.2. Antibodies, by source
6.3.2.1. Mice
6.3.2.2. Rabbits
6.3.2.3. Other sources
6.3.3. Antibodies, by research area
6.3.3.1. Oncology
6.3.3.2. Infectious diseases
6.3.3.3. Immunology
6.3.3.4. Neurobiology
6.3.3.5. Stem cells
6.3.3.6. Other research areas
CHAPTER 7. GLOBAL RESEARCH ANTIBODIES MARKET – BY APPLICATION
7.1. Introduction services
7.2. Proteomics
7.3. Drug development
7.4. Genomics
CHAPTER 8. GLOBAL RESEARCH ANTIBODIES MARKET - BY END USER
8.1. Introduction
8.2. Pharmaceutical & biotechnology companies
8.3. Academic & research institutes
8.4. Contract research organisations
CHAPTER 9. GLOBAL RESEARCH ANTIBODIES MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL RESEARCH ANTIBODIES MARKET - COMPANY
PROFILES
10.1.Biolegend, Inc.
10.2. Perkinelmer, Inc.
10.3.GenScriptCorporation.
10.4. Abcam PLC.
10.5. Bio-Rad Laboratories
10.6. Merck Millipore.
10.7. Lonza Group
10.8. Thermo Fisher Scientific.
10.9. Cell Signalling Technology, Inc.
10.10. F.Hoffmann La Roche Ltd.,
10.11. Danaher Corporation.
10.12. Becton, Dickinson and Company
10.13. International Medical Group.
10.14. Merck Group
10.15. Allianz SE.
CHAPTER 11. GLOBAL RESEARCH ANTIBODIES MARKET - COMPETITIVE
LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3.Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
